A Significant Shift in Medical Device Labelling Symbols
The latest amendment to the global labelling standard, ISO 15223-1:2021 (Amd 1:2025), was published on 5 March 2025. This update introduces crucial changes designed to enhance consistency and clarity in medical device labelling worldwide. This is not merely a minor visual update; it represents a major logistical undertaking for manufacturers, as it will necessitate the revision of almost every piece of artwork across their product portfolios.
The primary change involves a fundamental shift in the symbol for the Authorised Representative. Historically represented by EC REP (European Community Representative), the symbol has now been updated to a jurisdiction-specific format: [XX] REP.
Why the Symbol Changed: Terminology and Global Clarity
The European Commission requested this change to address two specific concerns:
- Terminological Alignment: The term “European Community” became obsolete following the EU’s legal consolidation under the Lisbon Treaty in 2009. The new EU REP symbol correctly reflects the modern regulatory entity.
- Eliminating Global Confusion: The use of the “EC” designation created a potential risk of confusion with the ISO 3166-1 country code for Ecuador (EC). Transitioning to EU REP eliminates this ambiguity in international trade.
Beyond the symbol itself, the amendment introduces a formalised definition for “Authorised Representative,” aligning it with established global frameworks like ISO 13485 to reduce ambiguity for manufacturers operating in multiple markets.
Strategic International Harmonisation
The shift to the [XX] REP format allows the symbol to be used globally. The placeholder [XX] is replaced by the relevant two-letter or three-letter country code from ISO 3166-1 (e.g., EU REP for the European Union, CH REP for Switzerland, or NZ REP for New Zealand).
Additionally, the amendment clarifies that if the name and address of the responsible entity (such as the manufacturer and the representative) are identical, there is no need to duplicate this information. Instead, all applicable symbols can be grouped next to a single address, streamlining label space and reducing redundancy.
Transition Periods and Implementation Deadlines
While the amendment has been published internationally, its formal integration into the EU regulatory framework depends on its harmonisation via citation in the Official Journal of the European Union (OJEU).
What Manufacturers Need to Know Now:
- Harmonisation Status: The amended standard has already received a positive outcome from the HAS consultant. Consequently, it has been recommended for citation in the OJEU as a harmonised standard for the EU Medical Device Regulation (MDR) 2017/745.
- No Immediate Need for Relabelling: There is currently no immediate requirement to change existing labels. Devices already certified and on the market can continue using the legacy EC REP symbol during the transition.
- Recommended Transition: A three-year transition period will be recommended to the European Commission. This allows manufacturers to update labels during regular revision cycles or when other modifications become necessary.
Preparing for the Logistical Impact
The implications of changing a single symbol on every piece of packaging, instructions for use (IFU), and pre-printed artwork are vast. Manufacturers often hold significant stock of pre-printed materials, and a mandatory change represents a substantial administrative and cost burden.
We advise manufacturers to begin preparing for these changes now. Incorporating the EU REP or [XX] REP symbol into upcoming label revisions is the most cost-effective way to ensure long-term compliance without disrupting market supply.
For support in navigating these labelling transitions or interpreting the latest ISO amendments, our consultancy team is available to assist with gap analyses and strategic regulatory planning.
Contact Us
For further information and personalised guidance, please feel free to reach out to Advena via either our website contact page, www.advenamedical.com, email (info@advena.com) or phone (01926 800153) to start a conversation today.
